Literature DB >> 22569691

[Data availability and morbidity profile in Colombia].

Oscar Bernal1, Juan Camilo Forero, María del Pilar Villamil, Rafael Pino.   

Abstract

OBJECTIVE: To characterize morbidity in the Colombian population by diagnosis, sex, age, region, and health coverage system, and evaluate the availability and quality of information on diseases in the country. A descriptive, cross-sectional study to analyze morbidity treated in outpatient visits, hospitalization, and emergencies in Colombia during the 2004-2008 five-year period.
METHODS: Based on Colombia's personal health records (Registro Individual de Prestación de Servicios-RIPS), diagnoses were classified according to World Health Organization cause groups. Each cause group for services utilization was differentiated by geographical region, sex, and type of affiliation to the health system.
RESULTS: Communicable disease diagnoses were more concentrated in younger age groups, while noncommunicable diseases were more frequent in older age groups. External causes (accidents, self-inflicted injuries, and violence) were a major cause of morbidity and more frequently affected the population aged 5-44 years. Communicable diseases were more prevalent in females (39.98%) than in males (28%), while males were more affected by external causes than females (18.5% and 7.3%, respectively).
CONCLUSIONS: Although diagnoses of noncommunicable diseases have increased in Colombia, infections continue to have an important presence in all age groups and health services delivery settings. This situation requires a review of health policies, not only to orient them toward improving the health of the population, but also toward bridging the services gap that exists among the country's different regions. Furthermore, although RIPS are a valuable source of health data, they need to be strengthened with a view to achieving information coverage for all or at least the vast majority of Colombians.

Entities:  

Mesh:

Year:  2012        PMID: 22569691     DOI: 10.1590/s1020-49892012000300001

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


  6 in total

1.  Mapping the residual incidence of taeniasis and cysticercosis in Colombia, 2009-2013, using geographical information systems: Implications for public health and travel medicine.

Authors:  Alfonso J Rodríguez-Morales; María Camila Yepes-Echeverri; Wilmer F Acevedo-Mendoza; Hamilton A Marín-Rincón; Carlos Culquichicón; Esteban Parra-Valencia; Jaime A Cardona-Ospina; Ana Flisser
Journal:  Travel Med Infect Dis       Date:  2017-12-27       Impact factor: 6.211

2.  Burden of disease in Nariño, Colombia, 2010.

Authors:  Anderson Rocha-Buelvas; Elizabeth Trujillo-Montalvo; Carlos Hidalgo-Patiño; Angela Hidalgo-Eraso
Journal:  Colomb Med (Cali)       Date:  2014-09-30

3.  Neurocysticercosis in Latin America: Current epidemiological situation based on official statistics from four countries.

Authors:  Roberto Rodríguez-Rivas; Ana Flisser; Luiz Fernando Norcia; Pedro Tadao Hamamoto Filho; D Katterine Bonilla-Aldana; Alfonso J Rodriguez-Morales; Arturo Carpio; Matthew L Romo; Agnès Fleury
Journal:  PLoS Negl Trop Dis       Date:  2022-08-29

4.  Inequalities in health by regime of affiliation to the health system in events of obligatory notification, Colombia, 2015

Authors:  Liliana Hilarión-Gaitán; Diana Díaz-Jiménez; Karol Cotes-Cantillo; Carlos Castañeda-Orjuela
Journal:  Biomedica       Date:  2019-12-01       Impact factor: 0.935

5.  Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review.

Authors:  Juan-Sebastian Franco; David Vizcaya
Journal:  Pharmacol Res Perspect       Date:  2020-10

6.  Trends in all-cause pneumonia and otitis media in children aged <2 years following pneumococcal conjugate vaccine introduction in Colombia.

Authors:  Gabriel Carrasquilla; Alexandra Porras-Ramírez; Sandra Martinez; Rodrigo DeAntonio; Raghavendra Devadiga; Carla Talarico; Diana C Caceres; Maria M Castrejon; Patricia Juliao
Journal:  Hum Vaccin Immunother       Date:  2020-09-23       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.